Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen
Vandana Singh 15 hours ago
Trading IdeasMoversNewsGeneralBiotechTop StoriesHealth CareLarge Cap
Revolution Medicines shares updated Phase 1/2 Rasonque data showing a 60.7% response rate and 76.6% 12-month survival in pancreatic cancer.
Revolution Medicines, Inc. (NASDAQ:RVMD) on Thursday reported encouraging updated results from its Phase 1/2 RMC-GI-102 open-label study of Rasonque (daraxonrasib) combined with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC).
The global, commercial-stage oncology company, which focuses on developing medicines for patients with RAS-addicted cancers, will present the findings during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics.
Rasonque Delivers Strong Pancreatic Cancer Response Rates
As of Sept. 28, 2026, 61 patients in the first-line metastatic PDAC cohort received 200 mg of Rasonque plus GnP, reaching a median follow-up of 18.3 months.
The updated analysis showed a confirmed objective response rate of 60.7%, including complete responses in 8.2% of patients.
The regimen achieved a 90.2% disease control rate and a median duration of response of 11.1 months.
Patients also reached a median progression-free survival of 12.8 months and a 12-month overall survival rate of 76.6%.
Consistent Safety Profile Builds On Earlier Data
The combination therapy maintained a safety profile consistent with what researchers previously observed for both Rasonque and GnP.
The update builds on findings that investigators presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.
In August, the U.S. Food and Drug Administration (FDA) approved Rasonque for metastatic PDAC, via the agency’s controversial fast-track drug review pilot program.
Revolution Medicines began treating patients in October in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer.
The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation.
RVMD Price Action: Revolution Medicines shares were up 2.24% at $163.00 during premarket trading on Friday, according to Benzinga Pro data.
Photo: Shutterstock
More on RVMD
Benzinga
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment settingResults…
